Patents by Inventor Adva Levi

Adva Levi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416750
    Abstract: An oligonucleotide is provided. The oligonucleotide comprising a nucleic acid sequence of at least one DNAzyme, the DNAzyme being capable of silencing at least one target gene of a bacteria to thereby render the bacteria susceptible to antibiotic treatment.
    Type: Application
    Filed: November 9, 2021
    Publication date: December 28, 2023
    Applicant: 1E Therapeutics Ltd.
    Inventors: Ido Bachelet, Almogit Horowitz, Alexander Rosenberg, Anastasia Shapiro, Ron Oshri, Ilana Kolodkin-Gal, Adva Levy-Zamir, Gat Krieger, Ella GILLIS, Shmulik ITTAH
  • Publication number: 20230265424
    Abstract: Provided herein are DNAzymes conjugated to an organic moiety and methods of facilitating entry of DNAzymes into bacteria, utilizing same. Also provided are methods of targeting bacterial target genes, methods of treating or inhibiting the progression of bacterial infections, and methods of increasing susceptibility of bacteria to an antibiotic, using the described DNAzymes, which are optionally capable of silencing at least one target gene of bacteria and/or rendering bacteria susceptible to antibiotic treatment.
    Type: Application
    Filed: October 3, 2022
    Publication date: August 24, 2023
    Applicant: 1E Therapeutics Ltd.
    Inventors: IDO BACHELET, Alexander Rosenberg, Adva Levy-Zamir, Roni Oshri, Nataly Mirlas-Neisberg, Michal Pearl, Tamar Zehavi-Chkola, Itzhak Zander
  • Publication number: 20060246095
    Abstract: Disclosed are recombinant multiple epitope polypeptides (MEPs) consisting of T cell epitopes derived from tumor-associated antigens capable of being presented by an antigen presenting cell (APC), the recombinant nucleic acid sequences and expression vectors encoding them, and host cells transfected with said expression vectors. Further described are LTB-MEP fusion proteins comprising the E. Coli heat labile enterotoxin subunit B (LTB) peptide fused to a MEP by a synthetic linker, the recombinant nucleic acid sequences and expression vectors encoding them and host cell transfected with said expression vectors. Further included are compositions for inducing an immune response against malignancies, pharmaceutical compositions and a transdermal drug delivery system for the treatment of malignant disorders. Also disclosed are methods for conferring immunity against malignancies and for the treatment of malignant disorders.
    Type: Application
    Filed: March 24, 2006
    Publication date: November 2, 2006
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, GAVISH-GALILEE-BIO APPLICATIONS LTD.
    Inventors: Tamar Peretz, Michal Lotem, Shoshana Frankenburg, Jacob Pitcovski, Adva Levi, Hanah Margalit, Yael Altuvia